Sign up
Pharma Capital

Acquisition gives Horizon Discovery a 'full and complete suite of tools' to power growth

Chris Claxton, VP Investor Relations & Corporate Communications at Horizon Discovery Group PLC (LON:HZD), discusses with Proactive their 'transformational' acquisition of GE healthcare business Dharmacon.

The US$85mln deal was announced in July and funded through cash and shares and an accompanying £80mln placing.


View full HZD profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.